Skip to main content
sdecoret - stock.adobe.com

Bauer Lab

The main focus of our research is the analysis of the phenotype and functional properties of different immune cell populations mainly in the context of clinical trials. By doing so, we are aiming for an in depth understanding of cellular virus-host interactions to support the development of novel therapeutic interventions, e.g. by prediction of biomarker that identifies target engagement and predicts response to therapeutic interventions.

 

The main focus of our research is the analysis of the phenotype and functional properties of different immune cell populations mainly in the context of clinical trials. By doing so, we are aiming for an in depth understanding of cellular virus-host interactions to support the development of novel therapeutic interventions, e.g. by prediction of biomarker that identifies target engagement and predicts response to therapeutic interventions.

 

About our research

Comprehensive monitoring of anti-viral immunity increases our understanding of virus-host interaction thus supporting identification of new biomarkers predictive of response to vaccination or treatment. To evaluate the impact of immunotherapies it is necessary to have reliable and validated monitoring tools available to analyze and assess immunogenicity endpoints in clinical trials.

Therefore the development, establishment and validation of different state-of-the-art immunoassays to be used as immunogenicity endpoint assays in clinical trials is a central aim of the Immune Monitoring Group. We also establish and conduct inter-laboratory round robin tests for immunological endpoint assay and data analysis standardization to ensure reliable data across trial site in multicenter trials.

We are currently escorting several clinical trials with the aim to evaluate efficacy and immunogenicity of novel vaccines and therapeutic interventions. In addition to the assessment of immunity in Hepatitis B virus-related interventional studies, immune responses towards various viral infections (SARS-Coronavirus-2, Epstein-Barr virus and HBV) are monitored as part of observational studies for different patient cohorts.

Our scientists at Bauer Lab

Dr. Tanja Bauer

Supervisor

Dr. Nina Körber

Post Doc

Manuela Laumer

Technical Assistant

Annika Willmann

MD student

Gesa Wilkens

MD student

Publications

Read more

2022 Scientific Article in EBioMedicine

Vogel, E. ; Kocher, K. ; Priller, A. ; Cheng, C.-C. ; Steininger, P. ; Liao, B.-H. ; Körber, N. ; Willmann, A. ; Irrgang, P. ; Held, J. ; Moosmann, C. ; Schmidt, V. ; Beileke, S. ; Wytopil, M. ; Heringer, S. ; Bauer, T. ; Brockhoff, R. ; Jeske, S. ; Mijočević, H. ; Christa, C. ; Salmanton-García, J. ; Tinnefeld, K. ; Bogdan, C. ; Yazici, S. ; Knolle, P. ; Cornely, O.A. ; Überla, K. ; Protzer, U. ; Schober, K. ; Tenbusch, M.

Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2.

2022 Scientific Article in Nature Communications

Körber, N. ; Priller, A. ; Yazici, S. ; Bauer, T. ; Cheng, C.-C. ; Mijočević, H. ; Wintersteller, H. ; Jeske, S. ; Vogel, E. ; Feuerherd, M. ; Tinnefeld, K. ; Winter, C. ; Ruland, J. ; Gerhard, M. ; Haller, B. ; Christa, C. ; Zelger, O. ; Roggendorf, H. ; Halle, M. ; Erber, J. ; Lingor, P. ; Keppler, O. ; Zehn, D. ; Protzer, U. ; Knolle, P.A.

Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents.

Contact

Dr. Tanja Bauer

Supervisor